Print

ERYtech Pharma's Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency  
6/13/2012 10:24:22 AM

LYON, France--(BUSINESS WIRE)--ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and rare diseases, announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) to its investigational product ENHOXY® for sickle cell disease.
//-->